Arixtra 7.5 mg/dose Interactions
There are 170 drugs known to interact with Arixtra 7.5 mg/dose (fondaparinux), along with 5 disease interactions. Of the total drug interactions, 99 are major, 65 are moderate, and 6 are minor.
- View all 170 medications that may interact with Arixtra 7.5 mg/dose
- View Arixtra 7.5 mg/dose disease interactions (5)
Most frequently checked interactions
View interaction reports for Arixtra 7.5 mg/dose (fondaparinux) and the medicines listed below.
- albuterol
- aspirin
- baclofen
- Benadryl (diphenhydramine)
- cetirizine
- cholecalciferol
- clonazepam
- colchicine
- Coumadin (warfarin)
- Effexor (venlafaxine)
- Fentanyl Transdermal System (fentanyl)
- fluconazole
- folic acid
- gabapentin
- lansoprazole
- Lasix (furosemide)
- Lomotil (atropine / diphenoxylate)
- losartan
- Lyrica (pregabalin)
- Macrobid (nitrofurantoin)
- melatonin
- metformin
- metoprolol
- naproxen
- omeprazole
- prednisone
- spironolactone
- Vitamin D3 (cholecalciferol)
- Zanaflex (tizanidine)
- Zofran (ondansetron)
Arixtra 7.5 mg/dose disease interactions
There are 5 disease interactions with Arixtra 7.5 mg/dose (fondaparinux) which include:
Report options
QR code containing a link to this page
More about Arixtra 7.5 mg/dose (fondaparinux)
- Compare alternatives
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: factor Xa inhibitors
- Breastfeeding
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.